Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...
Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...
Inside the Outbound System That Helped 200+ Marketing & Branding Agencies Build Predictable New Business London, ...
In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...
The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback